Eziopitant. Pfizer.

Abstract

Pfizer is developing ezlopitant, a neurokinin-1 antagonist, for the potential treatment of irritable bowel syndrome (IBS). The compound had undergone phase II trials in the US and Europe, and phase I in Japan for treatment of chemotherapy-induced emesis [290988], [320737], [329187]. A phase II, double-blind, randomized study was performed to assess the safety and efficacy of ezlopitant for the control of cisplatin-induced emesis. Treatment was well tolerated [290988]. Although the compound effectively controls emesis, it is less effective in controlling nausea, and development has been discontinued for the emesis indication [347367]. Ezlopitant has undergone a pilot study in 14 IBS patients [367631].

• Authors: S Evangelista
• Journal: Current opinion in investigational drugs (London, England : 2000) (Curr Opin Investig Drugs) Vol. 2 Issue 10 Pg. 1441-3 (Oct 2001) ISSN: 1472-4472 [Print] England
• PMID: 11890362 (Publication Type: Journal Article, Review)

Chemical References

• Benzylamines
• Bridged Bicyclo Compounds, Heterocyclic
• Gastrointestinal Agents
• Neurokinin-1 Receptor Antagonists
• ezlopitant

Topics

• Animals
• Benzylamines (adverse effects, metabolism, pharmacology, therapeutic use)
• Bridged Bicyclo Compounds, Heterocyclic (adverse effects, metabolism, pharmacology, therapeutic use)
• Clinical Trials, Phase II as Topic
• Colonic Diseases, Functional (drug therapy)
• Gastrointestinal Agents (adverse effects, metabolism, pharmacology, therapeutic use)
• Humans
• Neurokinin-1 Receptor Antagonists
• Structure-Activity Relationship